SLEEP APNEA IN CONGESTIVE HEART FAILURE - 09/09/11
Résumé |
Sleep apnea and congestive heart failure (CHF) are both common disorders, occurring in approximately 2% to 4% and 1% of the general middle-aged population, respectively.4, 96 There appears to be considerable overlap between the two disorders. In two studies,51, 64 approximately 40% to 50% of stable symptomatic outpatients with CHF had either obstructive sleep apnea (OSA) or Cheyne-Stokes respiration with central sleep apnea (CSR-CSA). Evidence is also accumulating that sleep-related breathing disorders can contribute to progression of heart failure and affect its prognosis. Several studies, for example, have described higher mortality rates in CHF patients with, than in those without, CSR-CSA.2, 31, 42 Other studies56, 64, 85 have demonstrated that nightly treatment of either type of sleep apnea with continuous positive airway pressure (CPAP) is associated with marked improvements in cardiac function and symptoms of heart failure.
Despite recent advances in the pharmacologic therapy of CHF, its prognosis remains poor. In the largest and longest study to date, although the angiotensin-converting-enzyme inhibitor, enalapril, reduced mortality compared with placebo, after 3.5 years, mortality among the enalapril treated group was still 35%.86 That is a death rate that rivals that of many malignancies.4 If the clinical outcome of CHF is to improve, therefore, novel approaches to its treatment will have to be developed. This article reviews data suggesting that one promising approach to improving the prognosis of CHF may be the diagnosis and specific treatment of sleep-related breathing disorders in those patients.
Le texte complet de cet article est disponible en PDF.Plan
| Address reprint requests to T. Douglas Bradley, MD, FRCPC, Sleep Research Laboratory, Room 1220, Rehabilitation Institute of Toronto, 550 University Avenue, Toronto, Ontario, M5G 2A2, Canada This work was supported by operating grants MT-11607 and MA-12422 to T. D. Bradley from the Medical Research Council of Canada. T. D. Bradley is a Career Scientist of the Ontario Ministry of Health. M. T. Naughton is a recipient of an Australian Lung Foundation Career Development Award and a Viertal Clinical Investigatorship. |
Vol 19 - N° 1
P. 99-113 - mars 1998 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
